Aeolus Pharmaceuticals (AOLS) 8-K Regulation FD Disclosure

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report: April 09, 2012 (Date of earliest event reported)
Aeolus Pharmaceuticals (Exact name of registrant as specified in its charter)
CA (State or other jurisdiction of incorporation)	000-50481 (Commission File Number)	56-1953785 (IRS Employer Identification Number)
26361 Crown Valley Parkway (Address of principal executive offices)		92691 (Zip Code)
949-481-9821 (Registrant's telephone number, including area code)
Not Applicable (Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure

Press release announcing that BARDA intends to exercise the second year option of our development contract

Item 9.01. Financial Statements and Exhibits

(a) Financial statements:
            None
(b) Pro forma financial information:
            None
(c) Shell company transactions:
            None
(d) Exhibits
            99.1       Press Release of Aeolus Pharmaceuticals dated April 09, 2012

SIGNATURE

      Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 09, 2012
AEOLUS PHARMACEUTICALS By:  /s/ Russell Skibsted                    
     Russell Skibsted
     Sr. Vice President and Chief Financial Officer

Exhibit Index
Exhibit No.	Description
99.1	Press Release of Aeolus Pharmaceuticals dated April 09, 2012